Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 12/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 4/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574207 | 0.91 | KDR (0.45) | NTRK1KDRRIPK1TEKBRAF | |
| SCHEMBL574065 | 0.90 | NTRK1 (0.54) | NTRK1KDRRETEPHB2IRAK4 | |
| SCHEMBL574328 | 0.90 | NTRK1 (0.54) | NTRK1KDRRETEPHB2TEK | |
| SCHEMBL827575 | 0.90 | NTRK1 (0.43) | NTRK1KDRGSK3BDYRK1ARET | |
| SCHEMBL574211 | 0.90 | NTRK1 (0.55) | NTRK1KDRRETEPHB2TEK | |
| SCHEMBL573369 | 0.90 | KDR (0.49) | NTRK1KDRRIPK1TEKBRAF | |
| SCHEMBL573650 | 0.89 | KDR (0.49) | NTRK1KDRRIPK1TEKBRAF | |
| SCHEMBL574231 | 0.87 | MET (0.43) | NTRK1KDRGSK3BDYRK1ARIPK1 | |
| SCHEMBL574093 | 0.86 | NTRK1 (0.51) | NTRK1KDRGSK3BDYRK1ARET | |
| SCHEMBL574276 | 0.86 | NTRK1 (0.42) | NTRK1KDRRIPK1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143293-B2 | disease caused by c-Abl kinase, c-Kit kinase, oncogenic forms, aberrant fusion proteins and polymorphs; 1-(3-t-butylisoxazol-5-yl)-3-(2-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)urea | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, PRKACA, BRAF | NTRK1 211/4885KDR 239/4885GSK3B 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.